CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • IPA Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Institutional
  • Shorts
  • News
  • Reddit
  • 6-K Filing

ImmunoPrecise Antibodies (IPA) 6-KImmunoprecise Antibodies LTD. 6-K

Filed: 10 Nov 21, 12:00am
Free signup for more
  • Track your favorite companies
  • Receive email alerts for new filings
  • Personalized dashboard of news and more
  • Access all data and search results
Sign up for free
Search this filing
?
Pre-defined:
Table of contents
    Filing tables
    Export all tables to Excel
    Filing exhibits
    SEC
    • 6-K Current report (foreign)
    • 99.1 Additional exhibits
    IPA similar filings
    • 30 Nov 21 Immunoprecise Antibodies LTD. 6-K
    • 24 Nov 21 Immunoprecise Antibodies LTD. 6-K
    • 12 Nov 21 Current report (foreign)
    • 10 Nov 21 Immunoprecise Antibodies LTD. 6-K
    • 29 Oct 21 Notice of Change of Auditor
    • 14 Oct 21 Immunoprecise Antibodies LTD. Form 6-K
    • 13 Oct 21 ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
    Filing view
    Share this filing
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 6-K
     
    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
     
    For the month of November 2021
     
    Commission File Number: 001-39530
     
    ImmunoPrecise Antibodies Ltd.
    (Translation of registrant’s name into English)
     
    3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8
    (Address of principal executive office)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F  ☐  Form 40-F  ☒
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
     

     


    EXHIBIT INDEX
     
    Exhibit No. Description
    99.1
     
    Press Release dated November 9, 2021.
     



    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     IMMUNOPRECISE ANTIBODIES LTD.
       
    Date: November 9, 2021By:/s/ Lisa Helbling
      Lisa Helbling
      Chief Financial Officer

    Finsight
    Resources
    • Knowledgebase
    • Log In
    • Register
    Company
    • About
    • Contact
    • Solutions
    Products
    • Deal Roadshow
    • DealVDR
    • Evercall
    • Finsight.com
    CapEdge
    • Earnings Calendar
    • Earnings Transcripts
    • EDGAR Filing Screener
    • IPO Calendar
    • Compliance
    • Privacy
    • Security
    • Terms
    AngelList LinkedIn